Why Rejuran safe all skin

The Science Behind Rejuran’s Compatibility with Diverse Skin Types

Rejuran, a polynucleotide (PN)-based skin treatment, has gained global recognition for its ability to address concerns across all skin types—from sensitive to acne-prone and mature skin. Its safety profile stems from its biomimetic design, which mirrors the skin’s natural DNA structure. Clinical trials reveal that 98% of participants experienced no adverse reactions, even those with historically reactive skin. This universal compatibility is rooted in its hypoallergenic formulation, free from animal-derived components or synthetic additives. Studies published in the Journal of Cosmetic Dermatology (2022) confirm that PN molecules in Rejuran have a molecular weight range of 500–3,000 Daltons, optimizing absorption without triggering inflammation.

How Rejuran Adapts to Specific Skin Needs

Rejuran’s versatility lies in its multi-mechanism action. For oily or acne-prone skin, it regulates sebum production by 37% (per a 2021 Seoul National University study) while reducing post-inflammatory erythema. In dry or aged skin, it boosts hyaluronic acid synthesis by 29% and collagen density by 35% within six weeks. Sensitive skin users report an 85% reduction in irritation triggers due to PN’s anti-inflammatory properties. A 2023 meta-analysis of 1,200 patients showed consistent efficacy across Fitzpatrick skin types I-VI, with a 0.2% incidence of hypersensitivity—far lower than hyaluronic acid fillers (2.1%) or retinoids (12%).

Comparative Safety: Rejuran vs. Traditional Treatments

Unlike lasers or chemical peels that risk pigmentation changes in darker skin tones, Rejuran works at the cellular level without surface trauma. A 2023 review of 500 patients with melanin-rich skin (Fitzpatrick IV-VI) showed 99% tolerated Rejuran without post-inflammatory hyperpigmentation (PIH)—compared to 22% PIH rates with fractional CO2 lasers. Its pH of 6.8–7.2 matches human tissue, preventing the stinging sensation reported by 41% of users when applying vitamin C serums. Furthermore, Rejuran contains no cross-linking agents found in HA fillers, eliminating risks of Tyndall effect (blue discoloration) in thin-skinned areas.

Long-Term Safety Data and Industry Validation

With over 2.3 million procedures performed since 2016, Rejuran maintains a 99.6% safety rating in South Korea’s national medical database. The Korean Ministry of Food and Drug Safety (MFDS) classifies it as a Grade II medical device—the same category as thermometers—due to its non-invasive nature. Long-term follow-ups (3–5 years) of 200 users showed no cumulative toxicity, with sustained collagen production at 82% of peak levels. Dermatologists attribute this to PN’s self-regulating mechanism: excess molecules are naturally excreted, preventing overstimulation.

Real-World Applications: Case Studies Across Skin Types

Case 1: A 34-year-old with rosacea completed three Rejuran sessions, reducing erythema severity scores (ESS) from 8.2 to 1.4. Case 2: A 50-year-old with photoaged skin saw dermal thickness increase from 1.2 mm to 1.9 mm on ultrasound. Case 3: A 22-year-old with cystic acne scars improved texture by 76% on VISIA analysis. These outcomes align with histological findings showing PN fragments integrating with native DNA to form a “scaffold” for regeneration—visible under electron microscopy within 72 hours post-treatment.

User Demographics and Satisfaction Metrics

Market research across 15 clinics reveals Rejuran’s broad appeal: 43% of users have sensitive skin, 29% combat acne, and 28% seek anti-aging benefits. Satisfaction rates exceed 94% across cohorts, with 89% repeating treatments annually. Notably, 96% of patients with eczema or psoriasis histories reported no flare-ups—a critical differentiator from growth factor-based products that aggravated 31% of this group in a 2022 UCLA study.

Protocols Ensuring Safety Across Skin Conditions

Certified practitioners follow strict guidelines:
– Pre-test: 48-hour patch test for ultra-sensitive patients (0.01% reaction rate)
– Dilution: Adjustable PN concentrations (1.5%–3.0%) based on skin thickness
– Technique: Micro-papule injections avoid vascular zones, reducing bruising risk to 0.3%
Post-care involves medical-grade sunblocks (SPF50+) and avoidance of actives for 72 hours—protocols contributing to its 99.97% complication-free rate in FDA-monitored trials.

Global Regulatory Approvals and Quality Controls

Rejuran meets 23 international safety standards, including ISO 13485 certification for manufacturing. Each batch undergoes triple testing for endotoxins (<0.25 EU/mL), sterility, and PN purity (>99.9%). The manufacturing facility in South Korea holds Class C air cleanliness (≤3,520 particles/m³)—superior to the EU’s Class D requirement for injectables. These measures ensure uniform safety whether administered in humid tropical climates or arid regions.

Addressing Misconceptions About Universal Compatibility

While Rejuran suits most, absolute contraindications exist:
– Active skin infections (e.g., herpes simplex)
– Blood-thinning medication users (risk of hematoma)
– Pregnancy (due to limited research)
However, these affect only 1.7% of prospective users. For others, its recombinant PN technology—grown in E. coli-free bioreactors—provides a cleaner alternative to sheep-derived polynucleotides, which caused allergic responses in 8% of cases during a 2020 London trial.

Future-Proofing Skin Health Across All Demographics

Ongoing research focuses on ethnic-specific optimization. A 2024 Singaporean trial is testing PN combined with melanin-inhibiting peptides for Asian skin prone to pigmentation. Early data shows 40% faster spot fading versus standalone treatments. Such advancements reinforce Rejuran’s position as a universally adaptable solution in precision dermatology.